Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;14(11):1164-1181.
doi: 10.2174/1567205014666170508121031.

Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

Javed Ahmad  1 , Sohail Akhter  2 , Md Rizwanullah  3 , Mohammad Ahmed Khan  4 , Lucie Pigeon  5 , Richard T Addo  6 , Nigel H Greig  7 , Patrick Midoux  5 , Chantal Pichon  5 , Mohammad Amjad Kamal  8
Affiliations
Review

Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

Javed Ahmad et al. Curr Alzheimer Res. 2017.

Abstract

Background: Alzheimer's disease (AD), a cognitive dysfunction/dementia state amongst the elders is characterized by irreversible neurodegeneration due to varied pathophysiology. Up till now, anti-AD drugs having different pharmacology have been developed and used in clinic. Yet, these medications are not curative and only lowering the AD associated symptoms. Improvement in treatment outcome required drug targeting across the blood-brain barrier (BBB) to the central nervous system (CNS) in optimal therapeutic concentration. Nanotechnology based diagnostic tools, drug carriers and theranostics offer highly sensitive molecular detection, effective drug targeting and their combination. Over the past decade, significant works have been done in this area and we have seen very remarkable outocome in AD therapy. Various nanoparticles from organic and inorganic nanomaterial category have successfully been investigated against AD.

Conclusion: This paper discussed the role of nanoparticles in early detection of AD, effective drug targeting to brain and theranostic (diagnosis and therapy) approaches in AD's management.

Keywords: Alzheimer's disease; blood brain barrier; diagnosis; nanomedicines; nanoparticles; theranostic.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Figures

Fig. (1)
Fig. (1)
Drawing presenting the nanoparticles facilitating drug/biologicals transport across the BBB: [A] on systemic application/absorption in blood stream, nanoparticles carrying AD’s drugs reached to the BBB, [B] get absorbed across BBB by following possible mechanisms (indicated here in figure), and [C] further reach the AD affected area and depending on their mode of action may act on the cholinergic system, amyloid plaque, tau protein and/or excessive oxidative load [Adapted and reprinted by permission from the Bentham Science for CNS Neurol Disord Drug Targets: Reference 98].
See this image and copyright information in PMC

References

    1. Prince M, Albanese E, Guerchet M, Prina M. World alzheimer report 2014: Dementia and risk reduction. 2014 www.alz.co.uk/research/WorldAlzheimerReport.
    1. Nabeshima T, Nitta A. Memory impairment and neuronal dysfunction induced by beta-amyloid protein in rats. Tohoku J Exp Med. 1994;174(3):241–49. - PubMed
    1. Popovic N, Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int J Pharm. 2006;314(2):120–26. - PubMed
    1. Potschka H. Targeting the brain-Surmounting or bypassing the blood-brain barrier. Handb Exp Pharmacol. 2010:411–31. - PubMed
    1. Ahmad MZ, Akhter S, Rahman Z, Ahmad J, Ahmad I, Ahmad FJ. Nanomedicine based drug targeting in Alzheimer’s disease: High impact of small carter. In: Atta-ur-Rahman, Choudhary MI, editors. Front Drug Design Discov. Vol. 6. 2014. pp. 716–39.